Subcutaneous Injection Guide | Investigational (Phase 3)
Retatrutide Injection Sites
Retatrutide (LY3437943) is an investigational triple-agonist GLP-1, GIP, and glucagon receptor agonist injected subcutaneously once a week. The DailyMed label for the Retatrutide Pen names three approved sites: abdomen, thigh, or upper arm. Below you'll find each site explained, the rotation schedule the label requires, prep steps, and which local reactions are worth watching.
Key Takeaways
- 3 DailyMed-approved sites: Abdomen, front or outer thigh, and upper arm (DailyMed RETATRUTIDE PEN label)
- Self-injection: Abdomen and thigh are suitable for self-administration. Upper arm is difficult to reach and control without a caregiver.
- Rotate with every dose: DailyMed label requires rotating injection sites each weekly injection
- Avoid damaged skin: Do not inject into tender, bruised, damaged, or scarred skin within any approved zone
- Investigational status: Retatrutide has no FDA-approved IFU yet. Site guidance follows the DailyMed pen label for this Phase 3 compound.
- Alcohol prep required: Clean the injection site with alcohol before each injection (DailyMed label)
3
DailyMed-Approved Sites
Once weekly
Dosing Frequency
~6 days
Half-Life (supports weekly schedule)
Investigational compound: Retatrutide (LY3437943) has not received FDA approval as of April 2026. Phase 3 trials are ongoing. Injection site guidance in this article is drawn from the DailyMed label for the Retatrutide Pen. Always follow your prescriber's instructions and the package insert that comes with your medication.
The 3 DailyMed-Approved Retatrutide Injection Sites
The DailyMed prescribing label for the Retatrutide Pen states: "Recommended injection sites: abdomen, thigh, or upper arm. Rotate injection sites each week." Those are the only three anatomical zones. Here's what each one looks like and when to use it.
Abdomen (Most Common for Self-Injection)
The abdomen is the most practical site for self-injection. You inject into the subcutaneous fat layer of the stomach area, not into muscle. The usable zone covers the soft tissue on the left and right sides of the navel, below the waistline, and toward the lower abdomen.
The DailyMed retatrutide label does not name a specific navel clearance distance. Standard subcutaneous injection guidance from Memorial Sloan Kettering Cancer Center (MSKCC) recommends avoiding the area immediately around the navel, where tissue is denser and injections are more uncomfortable. The same principle applies here: pick a spot within the abdominal zone where you can comfortably pinch at least 1 to 2 inches of soft tissue.
Practical tip: Many people find the lower abdomen, slightly to the left or right, is the most comfortable and accessible area. The skin there tends to have enough subcutaneous fat to allow a clean pinch if needed before inserting the needle.
Thigh (Front and Outer Only)
The front and outer thigh is a reliable alternative to the abdomen. Inject into the subcutaneous tissue of the middle third of the thigh, roughly midway between the knee and hip, on the front or outer side. This site is especially useful when abdominal skin is tender or when you have recently used that area.
Many people find the thigh easier to visualize and access, particularly while seated. Avoid the inner thigh, which has less subcutaneous fat and is more sensitive tissue.
Upper Arm (Caregiver-Assisted in Practice)
Practical limitation: The DailyMed label for retatrutide lists the upper arm as an approved site without specifying that another person must administer it. This is a key difference from Zepbound (tirzepatide), whose FDA prescribing information explicitly restricts the upper arm to caregiver administration. The retatrutide DailyMed label is less prescriptive because retatrutide is still investigational and its labeling has not gone through full FDA-approved IFU review. In practice, the posterior upper arm (tricep area) is difficult to reach and control correctly for self-injection, so most people who use the upper arm do so with caregiver assistance. Ask your prescriber whether self-injection into the upper arm is feasible for you given your anatomy and device type.
When the upper arm is used, the standard anatomical target is the posterior tricep area, where subcutaneous fat is adequate. The retatrutide label does not specify "back of" the arm in explicit terms the way some approved-drug IFUs do, but that is the anatomically practical location.
How to Rotate Retatrutide Injection Sites and Why It Matters
The DailyMed retatrutide label is direct: "Rotate injection sites each week." That is not optional guidance. Repeated injection into the same spot causes the subcutaneous fat tissue to thicken and become fibrous, a condition called lipohypertrophy. Once that happens, absorption from that site becomes erratic and unpredictable.
Because retatrutide has a half-life of approximately 6 days and is dosed once weekly, you return to each site roughly every 4 weeks when following a structured rotation. This 4-week cycle also aligns with the 4-week titration interval, making it straightforward to tie site rotation to your dose escalation calendar.
A Simple 4-Week Retatrutide Rotation Schedule
A consistent rotation pattern makes it easy to remember where you last injected. A 4-week cycle works well for most people on weekly dosing:
Week 1
Left abdomen
Week 2
Right abdomen
Week 3
Left thigh
Week 4
Right thigh
Repeat the cycle from Week 1 after Week 4. If a caregiver assists, the upper arm can substitute for any week in the cycle.
What Happens If You Do Not Rotate? (Lipohypertrophy)
Injecting into the same location every week causes lipohypertrophy: thickened, fibrous subcutaneous fat from repeated tissue trauma. The affected area may feel firm or rubbery under the skin. Beyond the cosmetic concern, lipohypertrophic tissue absorbs medication erratically. People who develop it sometimes see inconsistent weekly responses that have nothing to do with the dose itself.
If you develop a firm raised area at a previous injection site, avoid that spot until it resolves and mention it to your prescriber at the next appointment.
Preparing to Inject Retatrutide: Step-by-Step
Good preparation is most of the job. The steps below come from the DailyMed retatrutide label and standard subcutaneous injection technique from MSKCC.
What You Need
- Reconstituted retatrutide vial or pen device
- Appropriate insulin syringe if drawing from a vial (see the retatrutide reconstitution guide for mixing steps)
- Alcohol swabs
- Sharps disposal container
- Optional: gauze or cotton ball for post-injection pressure
Site Prep Steps
- Choose your site for this week from one of the 3 DailyMed-approved zones, rotating from last week's location
- Clean with an alcohol swab and allow the site to dry for 10 to 15 seconds before injecting (DailyMed label: "Clean the injection site with alcohol before injection")
- Pinch the skin gently if adequate subcutaneous fat is present, per MSKCC subcutaneous injection guidance
- Insert the needle at a 45 to 90 degree angle depending on needle length and tissue depth (shorter needles use 90 degrees; longer needles on leaner tissue use 45 degrees)
- Inject the dose slowly, withdraw the needle, and apply gentle pressure with gauze. Do not rub the site after withdrawing.
- Dispose of the needle immediately in a sharps container. Never recap used needles.
Does the Injection Site Affect How Well Retatrutide Works?
The DailyMed retatrutide label does not rank any approved site as clinically superior for outcomes. All three locations are considered effective subcutaneous delivery routes.
Retatrutide's subcutaneous bioavailability is approximately 95% based on Phase 1 pharmacokinetic data (Coskun et al., 2022), which is high relative to other compounds in this drug class. Very little drug is lost at the injection site regardless of which approved location you use. Claims about meaningful absorption differences between the abdomen, thigh, and upper arm circulate online but have no retatrutide-specific Tier 1 evidence behind them.
The Pharmacokinetic Case for Rotating on Schedule
With a ~6-day half-life, retatrutide levels stay detectable all week and reach steady state after 4 to 5 weeks of consistent dosing. Rotating sites keeps each dose absorbing from healthy, intact tissue. Lipohypertrophic spots absorb erratically and can flatten or spike the curve in ways that have nothing to do with your dose.
The GLP3Planner retatrutide calculator lets you visualize that drug level curve week to week, so you can see what consistent timing and proper rotation actually do to steady-state exposure.
Retatrutide Injection Site Reactions: What Is Normal, What Is Not
Minor local reactions are common with subcutaneous injections. Clinical data for retatrutide shows injection site reactions in approximately 5 to 15 percent of participants, typically mild redness, itching, or small lumps that resolve within a day or two.
Usually normal
- Small red bump or raised area at the site
- Mild itching that fades within hours
- Minor bruising from the needle
- Brief stinging or pinching during injection
Contact your provider
- Spreading redness or warmth around the site
- Pus or discharge from the injection point
- Swelling that worsens after 24 hours
- Signs of allergic reaction: hives, swelling away from site, difficulty breathing
Rotating sites each week and using correct technique reduce local reaction frequency. For a full breakdown of retatrutide adverse events beyond the injection site, see the retatrutide side effects guide.
Track Your Retatrutide Injection Schedule
Log each weekly dose and site with the free GLP3Planner calculator. Visualize retatrutide drug levels and stay on your titration schedule.
How to Inject Retatrutide: Video Demonstration
This demonstration by board-certified dermatologist Dr. Jason Emer, MD covers the full subcutaneous injection process including site selection, needle angle, and preparation steps. Subcutaneous injection technique is consistent across GLP-1 class drugs, making this 464,000-view walkthrough directly applicable to retatrutide pen and vial administration.
Dr. Jason Emer, MD. "HOW TO PREPARE AND INJECT PEPTIDES WITH DEMONSTRATION OF ALL STEPS | SEMAGLUTIDE." Published April 2024. 464,193 views. Subcutaneous injection technique shown is applicable across GLP-1 class drugs including retatrutide.
Retatrutide Injection Sites: Frequently Asked Questions
Where should I inject retatrutide?
The DailyMed label for the Retatrutide Pen specifies three recommended injection sites: abdomen, thigh, or upper arm. The abdomen and thigh are the standard choices for self-injection. Rotate among sites with every weekly dose and clean the site with alcohol before each injection.
How often should retatrutide be injected?
Retatrutide is injected subcutaneously once weekly, on the same day each week, with or without meals. The DailyMed label specifies weekly dosing. Retatrutide's half-life of approximately 6 days supports this schedule. Drug levels remain detectable throughout the week, reaching steady state after 4 to 5 weeks.
Can I self-inject retatrutide into my upper arm?
The upper arm is listed as an approved injection site on the DailyMed retatrutide label, but it is difficult to reach and control for self-injection. In practice, the abdomen and thigh are the two sites most suitable for self-administration. If using the upper arm, a caregiver should administer the dose.
What happens if you do not rotate retatrutide injection sites?
Repeated injection into the same spot causes lipohypertrophy: thickened, fibrous subcutaneous fat that absorbs medication erratically. The DailyMed label requires rotating sites with each weekly dose. If you develop a firm raised area at a previous injection site, avoid it and inform your prescriber at the next appointment.
Does the injection site affect how well retatrutide works?
The DailyMed label does not rank any approved site as clinically superior for retatrutide. All three sites are considered effective subcutaneous delivery routes. Retatrutide's bioavailability via subcutaneous injection is approximately 95% per Phase 1 pharmacokinetic data (Coskun et al., 2022), meaning very little drug is lost at the injection site regardless of which approved location you choose.
What skin should I avoid when injecting retatrutide?
Avoid skin that is tender, bruised, damaged, or scarred when choosing your injection spot within an approved zone. These conditions impair absorption and raise the risk of discomfort or local infection. Choose clean, intact subcutaneous tissue within the abdomen, thigh, or upper arm. Avoid the navel zone as standard subcutaneous technique.
What are common retatrutide injection site reactions?
Injection site reactions occur in approximately 5 to 15 percent of people using retatrutide in clinical data. Common reactions are mild redness, itching, or small lumps that resolve within a day or two. Rotating sites each week, choosing healthy skin, and using correct technique reduce the frequency of local reactions.
Why should you not inject near the belly button?
The tissue around the navel is denser than the surrounding subcutaneous fat, which can make the injection more uncomfortable and affect how evenly medication absorbs. Standard subcutaneous injection technique recommends avoiding this zone. The DailyMed retatrutide label does not specify an exact clearance distance; follow general subcutaneous injection guidance from your prescriber.
How do you inject retatrutide from a vial?
Injecting from a retatrutide vial requires reconstitution with bacteriostatic water first. Draw up the calculated dose into an insulin syringe, select an approved injection site, clean with alcohol, pinch skin gently, inject at a 45 to 90 degree angle, and dispose of the needle in a sharps container. See the reconstitution guide for full mixing steps.
What time of day should I inject retatrutide?
The DailyMed retatrutide label specifies injecting once weekly on the same day each week, at any time of day, with or without meals. Consistency of timing matters more than which specific time you choose. Using the GLP3Planner calculator to log your injection day helps maintain a consistent weekly schedule as you titrate through the dose steps.
References
- U.S. National Library of Medicine. Label: RETATRUTIDE PEN injection, solution. DailyMed. NIH. Available at: dailymed.nlm.nih.gov Primary source for all injection site facts: 3 approved sites, rotation, alcohol prep.
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Memorial Sloan Kettering Cancer Center. How to Give Yourself a Subcutaneous Injection Using a Prefilled Syringe. Available at: mskcc.org Source for general subcutaneous injection technique guidance including navel-zone avoidance.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013 Source for half-life approximately 6 days, once-weekly dosing pharmacokinetic rationale, and approximately 95% subcutaneous bioavailability.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Retatrutide (LY3437943) is an investigational compound that has not been approved by the FDA as of April 2026. Phase 3 trials are ongoing and this information may change. Do not start, stop, or change your dose or injection technique without guidance from a licensed clinician. Injection site guidance here is drawn from the publicly available DailyMed prescribing label and standard subcutaneous injection technique references; always defer to your prescriber and the package insert that comes with your medication. Results from clinical trials represent group averages and individual results vary.
Track Your Retatrutide Doses. Free.
Free pharmacokinetic calculator for retatrutide. Log doses, track injection sites, and visualize drug levels. No signup required.
Related Articles
Retatrutide Complete Guide
Dosing, results, calculator, and side effects hub for LY3437943.
Retatrutide Side Effects Guide
Retatrutide side effects from Phase 2 trial data.
Retatrutide Dosing Guide
Retatrutide dosing guide and titration schedule from 2mg to 12mg.
Retatrutide Reconstitution Guide
How to reconstitute retatrutide for injection with BAC water.